Skip to main content
. 2018 Mar 2;5(3):ofy004. doi: 10.1093/ofid/ofy004

Figure 3.

Figure 3.

Cumulative incidence for change of third component of firstline ART using death and loss to follow-up as competing events by treatment group (EFV vs bPI) in the overall cohort (A), and in analysis stratified by stage of HIV-associated disease at firstline ART initiation, for non-late ART initiators (B) or late ART initiators (C) over time. Abbreviations: bPI, boosted protease inhibitor; Change, includes changes in the third component of firstline ART for any reason or interruptions of treatment; EFV, efavirenz; firstline ART, first antiretroviral regimen; LI, patients initiating with CD4 <200 cells/µL or AIDS-defining event; LTFU, lost to follow-up, defined as no visits in the year before the closing date of data set for each site; Non-LI, patients initiating with CD4 >200 cells/µL and no AIDS-defining event.